Aerovate Therapeutics Files 8-K
Ticker: JBIO · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1798749
Sentiment: neutral
Topics: regulatory-filing, 8-k
Related Tickers: AVTE
TL;DR
AVTE filed a routine 8-K, no major news.
AI Summary
Aerovate Therapeutics, Inc. filed an 8-K on April 7, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine update for investors, indicating that Aerovate Therapeutics has submitted required disclosures to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K and does not disclose any new material events, risks, or financial changes.
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- 0001798749 (company) — Central Index Key
- 001-40544 (company) — SEC File Number
- 831377888 (company) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for Aerovate Therapeutics?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of April 7, 2025, fulfilling regulatory disclosure requirements.
When was this 8-K filing submitted?
This 8-K filing was submitted on April 7, 2025.
What is Aerovate Therapeutics, Inc.'s principal executive office address?
Aerovate Therapeutics, Inc.'s principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.
What is Aerovate Therapeutics's Standard Industrial Classification (SIC) code?
Aerovate Therapeutics's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing indicate any specific new developments or financial results for Aerovate Therapeutics?
No, this filing is a standard 8-K reporting 'Other Events' and 'Financial Statements and Exhibits' and does not specify any new material developments or financial results within the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding Aerovate Therapeutics, Inc. (JBIO).